European Union: The CJEU’s Decision In Brustle – The Implications For Stem Cell Research

Last Updated: 4 April 2014
Article by Jennifer Pierce and Christopher Birch

Stem cell research involves the use of embryonic stem cells (as well as adult stem cells) in research. As the embryonic stem cells used in research are derived from animals, including humans, stem cell research has become associated with ethical, moral and religious concerns. An issue which has arisen from those concerns is whether inventions which involve stems cells and their uses should be patentable.

The Biotechnology Directive

Patentability confers protection and commercial advantages for a patent owner. However, not all inventions are patentable. The Biotechnology Directive provides that the human body at the various stages of its formation and development, and the simple discovery of one of its elements, cannot constitute patentable inventions. Further, Article 6(2)(c) of the Biotechnology Directive expressly provides that the use of human embryos for industrial and commercial purposes is unpatentable.

Questions however remain: If uses of "human embryos" are not patentable, are stem cells derived from human embryos patentable or are methods of use of stem cells derived from human embryos patentable? In fact, what is meant by the term "human embryos" under the Biotechnology Directive?

The question of what constitutes a human embryo for the purposes of Article 6(2) (c) of the Biotechnology Directive was considered in the case of Oliver Brustle v Greenpeace ("Brustle").

The CJEU's decision in Brustle

Mr Brustle was the owner of a German patent concerning isolated and purified neural precursor cells. His patented invention used pluripotent embryonic stem cells (stems cells which are capable of developing into many different types of specialised cells but not all) to produce isolated and purified precursor cells which could be used in the treatment of neurological diseases such as Parkinson's disease. Greenpeace applied to revoke Mr Brustle's patent. The German court referred questions to the Court of Justice of the European Union ("CJEU") concerning, amongst other things, the meaning of (i) "human embryos"; and (ii) "uses of human embryos for industrial or commercial purposes" within the meaning of Article 6(2)(c) of the Biotechnology Directive.

The CJEU said that the concept of human embryos must be understood in a wide sense. In the court's opinion, the following constituted "human embryos":

  • A human ovum as soon as it is fertilised, if that fertilisation is such as to commence the process of development of a human being;
  • A non-fertilised human ovum into which the cell nucleus from a mature human cell has been transplanted;
  • A non-fertilised human ovum whose division and further development have been stimulated by parthenogenesis (if it is capable of commencing the process of development of a human being just as an embryo created by fertilisation could do).

However, disappointingly, the CJEU said it was for the referring court to decide whether a pluripotent stem cell removed from a human embryo at the blastocyst stage of development constituted a human embryo within the meaning of Article 6 (2)(c).

What are stem cells and why are they important for research?

Stem cells are unspecialised cells which have the ability to divide (proliferate), thus creating a supply of new identical (daughter) cells that, once divided, may develop into cells specialised for particular functions (for example, muscle cells, nerve or brain cells). It is this potential to proliferate and develop into specialised cells (and the manner in which proliferation and specialisation are regulated) which makes stem cells so important for medical research and the treatment of disease.

The law

In the UK, the use of stem cells in medical research is understandably subject to regulatory constraints. In addition, the patentability of inventions relating to stem cell research is subject to the provisions of the Directive on the legal protection of biotechnological inventions (the "Biotechnology Directive").

Although Mr Brustle's invention did not mention the use of human embryos, the stem cells were obtained at the blastocyst stage and at that time the removal of the cells resulted in the destruction of the embryo. The CJEU decided that an invention was to be excluded from patentability where the procedure required the prior destruction of human embryos or the use of human embryos beforehand, as base material, thus removing a possible loophole available where a patent application was silent as to the use of human embryos.

Concerning the question as to what is meant by "use of human embryos for industrial or commercial purposes", the CJEU said that scientific research involving the use of human embryos was not distinguishable from industrial and commercial use and therefore such scientific research use is not patentable. Following the CJEU's ruling, the case went back to the German court for final resolution. The German court followed the CJEU's reasoning but concluded that the Brustle patent was not entirely invalid. It held that stem cells removed at the blastocyst stage did not constitute "human embryos" as such cells, although pluripotent and capable of developing into different kinds of tissues, were incapable of developing into a complete human body. Therefore, if such cells could be produced without destroying the blastocyst (i.e. the "human embryo"), patent protection may be possible.

What does Brustle mean for future stem cell inventions?

Following the decision in Brustle, in 2012 the European Patent Office ("EPO") published new guidelines on the subject of patenting stem cell inventions. The new guidelines follow Brustle and make clear that a stem cell invention should not be directed to a human embryo nor should the invention have required prior destruction of a human embryo. Inventions relating to adult stem cells or human induced pluripotent stem cells or a method of removal of embryonic stem cells without destroying the embryo (a method of doing so was published in 2008) should be eligible for patent protection.

In 2013, the UK High Court in International Stem Cell Corporation v Comptroller General of Patents made a reference to the CJEU requesting clarification of the term "human embryos" in Article 6(2)(c). The High Court asked whether "human embryos" include unfertilised human ova whose division and further development have been stimulated by parthenogenesis and which, in contrast to fertilised ova, contain only pluripotent cells and are incapable themselves of developing into human beings.

On the face of it, International Stem Cell Corporation's patent applications claimed methods in which an unfertilised oocyte was activated by parthenogenesis and caused to develop into a blastocyst-like structure used to produce stem cells. Following Brustle, such an invention amounted to commercial or industrial use of a human embryo and as such was unpatentable. However, the applicant had argued before the UK Intellectual Property Office that in Brustle the CJEU was incorrect to find that an oocyte stimulated by parthenogensis was as capable as a fertilised ovum of producing a human being and, further, the applicant provided evidence that an oocyte stimulated by parthenogenesis could not ever develop into a human being.

The decision of the CJEU is awaited with interest. Stem cells without doubt have significant potential for treatment of disease. If inventions relating to cells which will never be capable of developing into a viable human being are to be excluded from patentability, the resulting commercial disadvantage for the biotechnology industry is likely to negatively impact the viability of future stem cell research and may have serious implications for the future management and treatment of disease.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Christopher Birch
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.